Chemed Co. (CHE) Insider Kevin J. Mcnamara Sells 4,000 Shares of Stock
Chemed Co. (NYSE:CHE) insider Kevin J. Mcnamara sold 4,000 shares of the business’s stock in a transaction on Thursday, August 23rd. The shares were sold at an average price of $319.50, for a total value of $1,278,000.00. Following the completion of the transaction, the insider now owns 139,491 shares of the company’s stock, valued at $44,567,374.50. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
CHE traded up $1.42 during trading on Friday, hitting $320.89. The company’s stock had a trading volume of 103,209 shares, compared to its average volume of 116,641. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.01 and a current ratio of 1.04. The company has a market capitalization of $5.13 billion, a PE ratio of 59.87, a price-to-earnings-growth ratio of 2.89 and a beta of 1.16. Chemed Co. has a twelve month low of $186.09 and a twelve month high of $335.99.
Chemed (NYSE:CHE) last issued its quarterly earnings results on Wednesday, July 25th. The company reported $2.81 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.77 by $0.04. The company had revenue of $441.80 million during the quarter, compared to the consensus estimate of $434.28 million. Chemed had a return on equity of 33.57% and a net margin of 11.00%. Chemed’s revenue was up 6.4% on a year-over-year basis. During the same period in the previous year, the firm posted $2.15 EPS. equities research analysts forecast that Chemed Co. will post 11.05 earnings per share for the current fiscal year.
A number of institutional investors and hedge funds have recently modified their holdings of CHE. Public Employees Retirement System of Ohio grew its stake in shares of Chemed by 911.6% during the 2nd quarter. Public Employees Retirement System of Ohio now owns 6,960 shares of the company’s stock valued at $2,240,000 after buying an additional 6,272 shares during the period. Bank of Nova Scotia purchased a new stake in shares of Chemed during the 2nd quarter valued at $18,440,000. Jane Street Group LLC grew its stake in shares of Chemed by 3,165.0% during the 2nd quarter. Jane Street Group LLC now owns 54,134 shares of the company’s stock valued at $17,421,000 after buying an additional 52,476 shares during the period. Millennium Management LLC purchased a new stake in shares of Chemed during the 2nd quarter valued at $40,386,000. Finally, MetLife Investment Advisors LLC grew its stake in shares of Chemed by 40.0% during the 2nd quarter. MetLife Investment Advisors LLC now owns 10,017 shares of the company’s stock valued at $3,224,000 after buying an additional 2,864 shares during the period. Institutional investors own 88.54% of the company’s stock.
Several brokerages have weighed in on CHE. ValuEngine downgraded Chemed from a “strong-buy” rating to a “buy” rating in a report on Thursday, August 2nd. Zacks Investment Research upgraded Chemed from a “hold” rating to a “buy” rating and set a $350.00 price target for the company in a report on Tuesday, July 31st. Finally, Royal Bank of Canada boosted their price target on Chemed to $321.00 and gave the company a “market perform” rating in a report on Monday, July 30th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $315.33.
Chemed Corporation provides hospice and palliative care services in the United States. It operates through two segments, VITAS and Roto-Rooter. The VITAS segment offers direct medical services, as well as spiritual and emotional counseling services to terminally ill patients. This segment offers its services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers.
Further Reading: How to Use the New Google Finance Tool
Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.